218 related articles for article (PubMed ID: 23335805)
21. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
mBio; 2017 May; 8(3):. PubMed ID: 28512091
[TBL] [Abstract][Full Text] [Related]
22. Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.
Douam F; Dao Thi VL; Maurin G; Fresquet J; Mompelat D; Zeisel MB; Baumert TF; Cosset FL; Lavillette D
Hepatology; 2014 Mar; 59(3):776-88. PubMed ID: 24038151
[TBL] [Abstract][Full Text] [Related]
23. Quantitative analysis of antibody to hepatitis C virus envelope 2 glycoprotein in patients with chronic hepatitis C virus infection.
Yuki N; Hayashi N; Kasahara A; Hagiwara H; Mita E; Ohkawa K; Katayama K; Fusamoto H; Kamada T
Hepatology; 1996 May; 23(5):947-52. PubMed ID: 8621173
[TBL] [Abstract][Full Text] [Related]
24. Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model.
Gao R; Gao W; Xu G; Xu J; Ren H
World J Gastroenterol; 2017 Jul; 23(28):5158-5166. PubMed ID: 28811710
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
[TBL] [Abstract][Full Text] [Related]
26. A laboratory-adapted HCV JFH-1 strain is sensitive to neutralization and can gradually escape under the selection pressure of neutralizing human plasma.
Song H; Ren F; Li J; Shi S; Yan L; Gao F; Li K; Zhuang H
Virus Res; 2012 Oct; 169(1):154-61. PubMed ID: 22846920
[TBL] [Abstract][Full Text] [Related]
27. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
Bose M; Mullick R; Das S; Das S; Karande AA
Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
[TBL] [Abstract][Full Text] [Related]
28. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.
Prentoe J; Bukh J
Front Immunol; 2018; 9():2146. PubMed ID: 30319614
[TBL] [Abstract][Full Text] [Related]
29. Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2.
Boo I; teWierik K; Douam F; Lavillette D; Poumbourios P; Drummer HE
Biochem J; 2012 Apr; 443(1):85-94. PubMed ID: 22240035
[TBL] [Abstract][Full Text] [Related]
30. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.
Velázquez-Moctezuma R; Law M; Bukh J; Prentoe J
PLoS Pathog; 2017 Feb; 13(2):e1006214. PubMed ID: 28231271
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies.
Stamataki Z; Coates S; Evans MJ; Wininger M; Crawford K; Dong C; Fong YL; Chien D; Abrignani S; Balfe P; Rice CM; McKeating JA; Houghton M
Vaccine; 2007 Nov; 25(45):7773-84. PubMed ID: 17919789
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.
Steinmann D; Barth H; Gissler B; Schürmann P; Adah MI; Gerlach JT; Pape GR; Depla E; Jacobs D; Maertens G; Patel AH; Inchauspé G; Liang TJ; Blum HE; Baumert TF
J Virol; 2004 Sep; 78(17):9030-40. PubMed ID: 15308699
[TBL] [Abstract][Full Text] [Related]
33. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1.
El-Diwany R; Cohen VJ; Mankowski MC; Wasilewski LN; Brady JK; Snider AE; Osburn WO; Murrell B; Ray SC; Bailey JR
PLoS Pathog; 2017 Feb; 13(2):e1006235. PubMed ID: 28235087
[TBL] [Abstract][Full Text] [Related]
34. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
35. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
[TBL] [Abstract][Full Text] [Related]
36. [Study of neutralization antibodie induced by DNA vaccine of HCV envelope protein 2 in mice].
Shao S; Zhou H; Tong Y; Ren Y; Chen Z
Wei Sheng Yan Jiu; 2011 May; 40(3):295-8. PubMed ID: 21695897
[TBL] [Abstract][Full Text] [Related]
37. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
[TBL] [Abstract][Full Text] [Related]
38. Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry.
Ciczora Y; Callens N; Penin F; Pécheur EI; Dubuisson J
J Virol; 2007 Mar; 81(5):2372-81. PubMed ID: 17166909
[TBL] [Abstract][Full Text] [Related]
39. [Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays].
Zhang K; Tan WJ; Deng Y; Li J; Wu XB; Ruan L
Bing Du Xue Bao; 2008 Jul; 24(4):287-94. PubMed ID: 18780632
[TBL] [Abstract][Full Text] [Related]
40. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.
Lavillette D; Tarr AW; Voisset C; Donot P; Bartosch B; Bain C; Patel AH; Dubuisson J; Ball JK; Cosset FL
Hepatology; 2005 Feb; 41(2):265-74. PubMed ID: 15660396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
